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ABSTRACT
AMYLOIDOGENESIS OF β-2-MICROGLOBULIN STUDIED BY MASS
SPECTROMETRY AND COVALENT LABELING
SEPTEMBER 2021
BLAISE GABRIEL ARDEN
B.S, UNIVERSITY OF CONNECTICUT
Ph.D., UNIVERSITY OF MASSACHUSETTS AMHERST
Directed by: Professor Richard W. Vachet

Amyloid-forming proteins are implicated in a number of debilitating diseases.
While many amyloid-forming proteins are well studied, the early stages of amyloidosis are
still not well understood on a molecular level. Covalent labeling, combined with mass
spectrometry (CL-MS), is uniquely well suited to provide molecular-level insight into the
factors governing the early stages of amyloidosis. This dissertation leverages CL-MS
techniques to examine the early stages of β-2-microglobulin (β2m) amyloidosis. β2m is the
protein that forms amyloids in the condition known as dialysis-related amyloidosis. An
automated CL-MS technique that uses dimethyl(2-hydroxy-5-nitrobenzyl) sulfonium
bromide as a labeling reagent was developed and used to measure energy barriers to the
initial pre-amyloid structural change of β2m under different amyloid-forming conditions.
The results represent the first ever measure of the activation barrier for a structural change
initiating amyloid formation. The results also give new mechanistic insight into β2m’s
amyloidogenic structural change, particularly the role of Pro32 isomerization. The catalytic
nature of Cu(II) as an initiator of the β2m pre-amyloid structural change was confirmed as
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it significantly lowered the energy barrier to this structural change. It also appears that,
when initiated by acid, the Pro32 isomerization may no longer be the rate limiting step in
this process.
The same technique was further used to investigate the β2m structural change
caused by its interaction with an amyloidogenic variant of β2m called ΔN6-β2m, which is
missing its first six N-terminal residues. Both primary and secondary nucleation events
involved in the β2m/ΔN6-β2m interaction were investigated. The measured barrier for the
primary nucleation event seems to indicate that, like the acid induced structural change of
β2m, the isomerization of Pro32 may not be the rate determining step. However, the
measured barrier for the secondary nucleation event, similar to that of the Cu(II) induced
structural change, indicates that the isomerization of Pro32 is the rate determining step.
The use of point mutants gives further detail on the crucial residues and regions of the
proteins required for a productive interaction to yield amyloids. The new kinetic and
thermodynamic information gained in this work yields new insight into the mechanistic
details of the biomedically important process of β2m amyloidosis.
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CHAPTER 1
INTRODUCTION
1.1 Amyloidosis
Protein folding diseases involve the misfolding or altered folding of proteins in the
body and can lead to negative, sometimes fatal consequences. A subset of protein folding
diseases are amyloid related diseases. Amyloids are insoluble protein aggregates
characterized by their fibrillar morphology composed of β-sheet rich structures. Amyloid
fibrils are implicated in well-known neurodegenerative diseases, such as Alzheimer’s and
Parkinson’s diseases, but are also associated with over 20 other human diseases, each
involving a different protein. Amyloid fibril formation is not only seen in the brain (as in
Alzheimer’s and Parkinson’s diseases), but can be found in other soft tissues, such as the
pancreas (in the case of islet amyloid polypeptide or amylin) or in the joints of dialysis
patients (in the case of β-2-microglobulin).1,2 Amyloid fibril formation typically begins
with partial protein unfolding (or partial folding by an unstructured protein) into an
intermediate followed by formation of soluble oligomeric species. The partially structured
intermediate or oligomeric intermediates then self-assemble into a nucleus enriched in βsheet structure. Growth of the nucleus by β-sheet extension leads to larger protofibrillar
aggregates that eventually form mature insoluble fibrils.1–6
While general aspects of amyloid formation are well understood for many different
amyloid-forming proteins, molecular-level information about the early stages of the
amyloid reaction is only beginning to be revealed for most amyloid systems. The early
steps of the reaction are important to understand because interrupting the reaction at these

1

stages can be one of the most effective means of preventing eventual fibril formation.
Furthermore, evidence indicates that pre-amyloid oligomeric intermediates are pathogenic
in some cases.7–10 For some proteins, the global structural properties of amyloidogenic
intermediates have been studied, but insights into amino acid-level structural changes are
only starting to emerge for some amyloid protein systems.
1.2 β-2-microglobulin
One amyloid disease, dialysis-related amyloidosis (DRA), occurs when kidney
function is impaired and patients undergo long term hemodialysis. In DRA, β-2microglobulin (β2m) accumulates and aggregates, primarily in bone and joint tissue.11 β2m
is a small (~12 kDa) 99 residue protein comprised of 7 β-strands (A-G) organized in an
anti-parallel β-sandwich held together by a disulfide bond (Figure 1.1).12–14 It is a part of

Figure 1.1: A breakdown of the structure of β2m. a) A cartoon representation of β2m
(PDB: 2XKS). b) A representation of the nomenclature and connectivity of the β-strands
in β2m. The green line represents the disulfide bond between the B strand and the F strand.
c) The amino acid sequence of β2m. Arrows above the sequence show which residues
make up each β-strand. The lines between the arrows represents the loops and unstructured
regions between β-strands.
2

the major histocompatibility complex (MHC) class I molecule and is present in all
nucleated cells in humans.
In patients with renal failure undergoing long term hemodialysis, the kidneys
cannot keep up with the body’s natural turnover of MHC I and β2m is not effectively
removed, causing its concentration to increase up to 60-fold. Eventually, β2m forms
amyloid fibrils in the joints of these patients.11 The cause of β2m amyloidosis is still not
well understood, but increased protein concentrations alone are insufficient. The resulting
DRA can lead to arthralgia, carpal tunnel syndrome, and bone cysts and in extreme cases,
death.15 Several in vitro methods of inducing β2m amyloidogenesis have been established,
including the addition of Cu(II), low pH, exposure to trifluoroethanol (TFE), and
incubation with β2m truncation mutants, among others.16–19
The induction of amyloidosis is characterized by a hallmark structural change
where native β2m monomers become destabilized and amyloid competent. In natively
folded β2m, the His31-Pro32 bond, contained in the loop between strands B and C (the BC
loop), adopts an unfavorable cis conformation stabilized by the N-terminal region of the
protein. Cis-trans isomerization (CTI) of Pro32 in β2m has been identified as the rate
determining step preceding β2m amyloid formation.20–24 Displacement of this strand
through truncation or interactions with metals or other molecules promotes CTI of Pro32
and subsequent conversion into the amyloidogenic precursor.25 This structural change
causes a repacking of the protein’s hydrophobic core, particularly exposure of Phe30
(contained on the BC loop) and burial of Trp60 (contained on the DE loop), and other
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Figure 1.2: Pre-amyloid structural change of β2m from the native conformation (green) to
the amyloid competent conformation (grey) characterized by the cis-trans isomerization of
Pro32. Other key rearrangements include the exposure of Phe30 and the burial of Trp60.
structural changes that facilitate aggregation (Figure 1.2).20–24,26–30 This conformational
change results in subsequent oligomerization before eventual amyloid fibril formation.20–24
1.3 Mass Spectrometry and Covalent Labeling
The level of molecular detail available with X-ray crystallography and nuclear
magnetic resonance (NMR) have made these popular tools for the analysis of amyloids,
although most amyloid systems are not readily amenable to these techniques. The
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application of these techniques has been somewhat limited in scope, however, because
most pre-amyloid species are too short-lived, exist in mixtures, and cannot be readily
crystallized. Low time resolution and need for high sample purity further limit their utility.
Mass spectrometry (MS) has emerged as a valuable tool for investigating amyloidforming proteins because of its high sensitivity, specificity, and balance of analysis speed
and moderate structural resolution. In contrast to NMR, it is not limited in terms of protein
molecular size and can provide structural information in protein mixtures. Using MS to
analyze protein structure typically requires encoding a protein’s structural information into
its mass and then detecting proteolytic fragments of that protein to localize the encoded
structural information. One technique finding increased usage in the study of amyloidforming proteins is covalent labeling. Covalent labeling (CL) has been coupled with MS
to obtain insight into protein topologies, conformations, and interactions at residue
level.31–33 In CL-MS, a protein or protein complex is reacted with a reagent that covalently
modifies the side chains of solvent exposed amino acids. A wide range of reagents have
been developed and utilized in CL-MS experiments, both ones that react with specific
amino acids30 and those that react with a broad range of amino acids.34 After the labeling
reaction, which encodes the structural information, the protein is analyzed in a manner
identical to most proteomics experiments: the protein is enzymatically digested, the
resulting peptides are separated by liquid chromatography (LC), and these peptides are then
sequenced by tandem mass spectrometry (MS/MS) to identify the modified residues. Most
CL-MS experiments are conducted by comparing the modification percentages of a given
protein under one condition to that of the same protein under another condition. Changes
in the modification extent can reveal conformation changes, binding sites, and protein-
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protein interfaces. CL-MS has unique attributes that enable this technique to reveal
structural details about amyloid-forming proteins that is not accessible by other techniques.
Two important features of CL-MS are its ability to analyze proteins in complex mixtures
and to obtain structural information on protein systems that are undergoing structural
changes on the timescales of minutes.
One specific type of CL, oxidative labeling, involves the covalent modification of
solvent exposed amino acid side chains by reactive oxidants. This technique is useful for
investigating protein-protein interaction sites by revealing differences in exposure of amino
acid residues of protein monomers and complexes. In one example, Li et al. used fast
photochemical oxidation of proteins (FPOP) to monitor the aggregation of Aβ1-42.35 The
changes seen in percent modification of the peptide over time showed several distinct
stages of aggregation. Using a nucleation-autocatalytic growth mechanism, the researchers
were able to model Aβ1-42 amyloidosis. They propose rapid dimer and small oligomer
formation followed by nucleation of larger oligomers from these smaller species. This
nucleation allows for catalysis of protofibril formation that eventually leads to formation
of full amyloid fibrils. Further analysis via digestion and LC-MS/MS illustrates that
association of Aβ1-42 is driven by hydrophobic interactions of residues 16-27.
Oxidative labeling has also been used to investigate the conversion of the prion
protein’s cellular form, PrPc, into its β-oligomeric form, PrPb.36 Isotopically labeled H2O2
(H216O2 and H218O2) were used to label Met and Trp residues in each conformer. After
labeling, both forms of PrP were combined and analyzed by LC-MS/MS. The extent of
modification on each form shows increased labeling on Met129, Met138, and Met213 of
PrPc and increased labeling on Trp99, Met112, Met134, Met139, and Met206 of PrPb.
6

These labeling differences are due to the rotation of the β1-H1-β2 loop away from the core
of the protein during the aggregation process.
FPOP has also been leveraged to look at structural differences between WT β2m
and its naturally amyloidogenic variant ΔN6-β2m which is missing the first 6 residues.
Cornwell et al. were able to determine 6 residues with significant differences in oxidation
between the two proteins.26 Unsurprisingly, most of these residues are near the N-terminal
truncation. Through comparison with hydrogen deuterium exchange (HDX)/MS, it is
revealed that all 6 of these residues fall in regions of ΔN6-β2m that are more dynamic than
WT β2m. These results suggest that a reorganization of side chains in ΔN6-β2m as
compared to WT β2m may lead to its high amyloidogenicity.
Metal catalyzed oxidation (MCO), another form of oxidative labeling, was used to
identify the Cu(II) binding site of β2m. MCO reactions can quickly capture information on
the Cu(II) binding site under conditions where the concentration of β2m is low enough (~2
μM) that there is no appreciable dimerization.16,29,37 Our group was able to use this
technique to identify the binding site of Cu(II) on monomeric β2m. This binding site
involves the N-terminal amine, the backbone amide between Ile1 and Gln2, His31, and
Asp59.27 These data give insight into how metal binding induces the pre-amyloid structural
change of β2m. In fully unfolded β2m, all four His residues can bind Cu(II), showing the
specificity of the particular Cu(II) binding site that triggers the pre-amyloid structural
change.38 In addition, it was shown that Ni(II) binds to β2m in a slightly different way that
does not lead to amyloid formation.39 A ‘detuned’ variation of the MCO reaction that
allows modification of residues within 10 Å shows a conformational change repositioning
Arg3 and Asp59.27 This subtle change allows for salt bridge formation in β2m dimers.40
7

Dimers and tetramers of β2m formed by initiation with Cu(II) were also investigated and
slight binding site changes were found that are consistent with the loss of Cu(II) from β2m
that occurs during the amyloid forming process.29,37
Residue-specific and pseudo-specific CL reagents can be used as a straightforward
method for mapping binding sites because protein-ligand binding often involves interaction
with specific side chains. Liu et al. were able to use CL to identify the binding sites of β2m
inhibitors rifamycin SV and doxycycline and another small molecule, suramin, which binds
to β2m but does not inhibit amyloid formation.41 Several labeling reagents were used in
parallel to increase confidence in binding site determination: diethylpyrocarbonate
(DEPC), which labels several residues, including His, Lys, Thr, Ser, and Tyr; 2,3butanedione (BD), which labels Arg residues; and the combination of 1-ethyl-3-(3(dimethylamino) propyl) carbodiimide (EDC) and glycine ethyl ester (GEE), which labels
Asp and Glu residues. The labeling reagents were each reacted with β2m in the presence
or absence of small molecule ligand. Analysis by LC-MS/MS revealed the binding sites of
rifamycin SV and doxycycline are regions of β2m known to mediate amyloid-competent
tetramer formation. Suramin was found to interact with residues not known to facilitate
formation of any oligomers. Further studies endeavored to use CL to determine the binding
site of another amyloid inhibitor epigallocatechin-3-gallate (EGCG).42
β2m forms discrete, even-order oligomers including dimers, tetramers, and
hexamers.37 Selective CL with MS can be used to characterize these oligomeric species.
Mendoza et al. studied the interfaces between monomer units in β2m dimers and tetramers
using DEPC, BD, and sulfo-N-hydroxysuccinimide acetate (NHSA) as complementary
labeling reagents.43,44 The extent of labeling of β2m monomers and the oligomers were
8

compared to gain insight into the oligomeric interfaces. The dimer interface was found to
be formed by an antiparallel arrangement of the ABED β-sheets of two monomers. The
labeling pattern of the tetramer indicates an interface between the D β-strands of one dimer
and the G β-strands of another dimer.
One residue specific covalent labeling reagent, Koshland’s reagent (2(Bromomethyl)-4-nitrophenol) is a tryptophan specific covalent label that has been used to
investigate solvent accessibility of tryptophan residues. However, use of Koshland’s
reagent is limited due to its lack of solubility in aqueous solution. The reactivity of
Koshland’s reagent also varies greatly with pH of the solution and the molecule can
hydrolyze rapidly at low pH. In addition, at various pHs, Koshland’s reagent can also react
with and label cysteine and tyrosine residues.45,46 To avoid the issues surrounding the use
of Koshland’s reagent, a variant was created which is soluble in aqueous solutions,
dimethyl(2-hydroxy-5-nitrobenzyl)sulfonium bromide (HNSB) (Figure 1.3). This reagent
is still selective for tryptophan residues, but has also been known to label free cysteine
residues to some extent, especially at low pH. HNSB is more stable than Koshland’s
reagent especially under acidic conditions, allowing for structural changes in protein to be
monitored under a wider variety of incubation conditions.47

Figure 1.3: Reaction of HNSB with a Trp residue, yielding a mass addition of 151 Da.
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Proteins or peptides that are labeled by HNSB can be analyzed by liquid
chromatography mass spectrometry (LC-MS) to determine the extent and site(s) of
labeling. From the MS data, a weighted average of the extent of tryptophan modification
by HNSB can be calculated. The large change in solvent accessibility of Trp60 in β2m
provides an excellent way to monitor the initial structural change that causes the conversion
of the protein into the amyloidogenic precursor. Since there are only two Trp residues in
β2m and only the Trp60 moves during the pre-amyloid structural change under most
conditions, whole protein analysis CL-MS experiments can be carried out without
proteolytic digestion or MS/MS, further simplifying experimentation.
1.4 Dissertation Overview
In this dissertation, a CL-MS method has been developed to monitor the burial of
Trp60 in β2m as a proxy for the pre-amyloid structural change characterized by the CTI of
Pro32. This technique was leveraged to gather energetic and mechanistic information about
reactions leading to the amyloid competent state of β2m. This work represents the firstever measurements of, not only the energy barrier to the pre-amyloid structural change of
β2m, but of any structural change leading to amyloid formation. In addition to the
knowledge gained about the β2m amyloid forming process, this work yields new insights
that are applicable to all amyloid systems.
In chapter 2 (published data), the CL-MS method using HNSB labeling was
developed to monitor the burial of Trp60 in β2m as a function of time as a means of
determining the rate of β2m’s amyloidogenic switch. These rate measurements were then
used to determine the energy barriers associated with this structural switch under different
amyloid forming conditions. The results confirmed the catalytic nature of Cu(II) by
10

demonstrating the significant drop in activation energy when Cu(II) is used as the amyloid
inducer of β2m. TFE also acts by reducing the energy required for the CTI of Pro32, but
not by nearly as much as Cu(II). Finally, it was revealed that when induced by low pH, the
CTI of Pro32 may no longer be the rate determining step of β2m amyloidogenesis.
In chapter 3, the same CL-MS method is used to probe the primary and secondary
nucleation dependent mechanisms of β2m amyloidosis as induced by interaction with the
amyloidogenic variant ΔN6. Activation energy barriers for both the primary and secondary
nucleation dependent mechanisms were determined. Additional work has begun to probe
some of the molecular factors governing these energy barriers for each mechanism. The
results show another structural change during the lag phase under primary nucleation
conditions and indicate that the CTI of Pro32 may no longer be the rate determining step.
The removal of the lag phase is demonstrated under secondary nucleation conditions as
well as evidence that the CTI of Pro32 is the rate determining step when initiated by
amyloid seeds. This chapter also leaves room for particularly interesting future work
towards possible molecular factors able to inhibit amyloid seeding.
Chapter 4 summarize the work completed towards this dissertation. It also
illustrates a myriad of ways in which this HNSB Trp labeling technique can be applied to
further investigation of amyloidosis. Specifically, determination of the method of action of
amyloid inhibitors, cross-seeding of β2m with other amyloid systems, and investigations
into another amyloidogenic variant of β2m with interesting structural features, among
others.
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CHAPTER 2
MEASURING THE ENERGY BARRIER OF THE STRUCTURAL CHANGE
THAT INITIATES AMYLOID FORMATION IN β-2-MICROGLOBULIN
2.1 Introduction
The formation of protein amyloid fibrils is associated with numerous devastating
human diseases, including Alzheimer’s, Parkinson’s, and type II diabetes.1,2 Amyloid fibril
formation typically begins with partial protein unfolding (or partial folding by an
unstructured protein) and formation of soluble oligomeric species before progressing to
primary nucleation and elongation events that involve aggregate formation via the addition
of monomers.1–6 For several amyloid protein systems, a combination of new experimental
and theoretical tools have recently led to a greater understanding of the kinetics and
thermodynamics the amyloid pathway,3–6 but almost no kinetic or thermodynamic
information is available for the initial structural change for any amyloid system. Even so,
it is generally recognized that measurements of kinetics and thermodynamics for amyloid
systems more fully reveal the complex mechanisms involved in the process and can help
better predict amyloid behavior under in vivo conditions that are more difficult to study
directly.
We have sought to obtain the first-ever kinetic and energetic information about the
initial structural change in amyloid formation using the protein β-2-microglobulin (β2m)
as a model system. In patients with renal failure undergoing long term hemodialysis, β2m
is not effectively removed, causing its concentration to increase up to 60-fold. Eventually,
β2m forms amyloid fibrils in the joints of these patients.7 The cause of β2m amyloidosis is
not well understood, but increased protein concentrations alone are insufficient. Several in
16

vitro methods of inducing β2m amyloidogenesis have been established, including the
addition of Cu(II), low pH, exposure to trifluoroethanol (TFE), and incubation with β2m
truncation mutants, among others.8–11
Cis-trans isomerization (CTI) of Pro32 in β2m has been identified as an important
structural change preceding β2m amyloid formation.12–16 In natively folded β2m, the
His31-Pro32 peptide bond adopts a cis conformation stabilized by the N-terminal strand.
Displacement of this strand through truncation or interactions with metals or other
molecules promotes CTI of Pro32 and subsequent conversion into the amyloidogenic
precursor.17 This structural change causes a repacking of the protein’s hydrophobic core,
particularly exposure of Phe30 and burial of Trp60, and other structural changes that
facilitate aggregation.12–16,18–22 Subsequent oligomerization to higher-order oligomers
occurs before eventual amyloid fibril formation.12–16
The large change in solvent accessibility of Trp60 provides an excellent way to
monitor the initial structural change that causes the conversion of the protein into the
amyloidogenic precursor. Here, we use a covalent labeling (CL) mass spectrometry (MS)
method22,23 to monitor the burial of Trp60 as a function of time as a means of determining
the rate of β2m’s amyloidogenic switch. These rate measurements are used to determine
the energy barriers associated with this structural switch under different amyloid forming
conditions. Cohen et al. have recently reported energy barriers to the nucleation and
elongation phases of amyloid formation by amyloid-β peptide,4 but to the best of our
knowledge, our measurements represent the first energy barriers ever measured for the
structural change that initiates amyloid formation. Such measurements will be useful for
more deeply understanding the mechanistic details of this process.
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Figure 2.1: Experimental scheme for CL-MS of β2m using the reagent HNSB.
2.2 Experimental
Covalent labeling MS (CL-MS) along with fluorescence spectroscopy and dynamic
light scattering (DLS) were used to monitor the structural and oligomeric changes of β2m
under different amyloid forming conditions. CL-MS uses reagents to covalently modify
solvent accessible amino acid residues,23 with liquid chromatography MS (LC-MS)
providing a readout of the extent of the modification (Figure 2.1 and Figure 2.2). The Trpspecific covalent labeling reagent dimethyl(2-hydroxy-5-nitrobenzyl) sulfonium bromide
(HNSB) was used to monitor Trp60 burial over time by reacting it with β2m for 45 or 90 s
at different time points after initiating amyloid formation with Cu(II), acid (at pH 3.5), or
20% TFE. The inherent reactivity of Trp with HNSB is lower at pH 3.5, and so a longer
reaction time (i.e., 90 s) was used for those experiments. In all cases, the reaction is
quenched by the addition of L-Trp and quickly desalted prior to MS analysis (Figure 2.1).
Covalent Labeling Sample Preparation. For all metal and TFE experiments, a 75
µM stock of β2m was made in 25 mM MOPS and 150 mM potassium acetate at pH 7.4.
For all acid experiments, a 150 µM stock of β2m was made in HPLC water. For all
18

Figure 2.2: Example electrospray ionization mass spectra of β2m, showing a decreased
extent of covalent labeling with HNSB 30 min after adding Cu(II). The asterisk (*)
indicates the HNSB-labeled β2m peaks in the mass spectra.
experiments, molar ratios of metal to β2m were chosen such that 95% of proteins in
solution were bound (based on previously reported measurements) and were as follows:
Cu 2:1, Zn 4:1, and Ni 16:1.24,25
Thioflavin T Fluorescence. Fluorescence experiments were performed on a PTI
QuantaMaster 4 SE spectrofluorometer. Measurements were taken at excitation and
emission wavelengths of 437 nm and 483 nm, respectively. Cu(II) initiated samples
contained 25 mM MOPS (at pH 7.4), 150 mM potassium acetate, 500 mM urea, 50 μM
β2m, 80 μM ThT and were equilibrated at 37 °C for 15 minutes before adding Cu(II). After
the addition of 100 μM Cu(II), the sample was immediately analyzed. Acid initiated
samples contained 108 μM β2m and 160 μM ThT. Analysis was started immediately after
introduction of β2m into the acidic buffer.
Dynamic Light Scattering. DLS was performed on a Malvern Zetasizer Nano ZSP
set in size analysis mode. Data collection was performed at 22 °C. Samples contained 30
μM β2m in 150 mM citrate buffer at pH 3.5 and were analyzed immediately after
introduction of β2m into the acidic condition.
19

Proteolytic Digestion and LC/MS/MS. HNSB labeled β2m samples were digested
using chymotrypsin. First, labeled β2m samples were unfolded by 50 mM TEA with 10%
ACN at 50°C for 45 min. Next, disulfide bonds were reduced by reaction with TCEP at
37°C for 15 min and cysteine’s alkylated by reaction with iodoacetamide at room
temperature for 30 min. Immobilized chymotrypsin was then added to yield an
enzyme/protein ratio of 1:10 and incubated at 37°C for 3 hours. Digested samples were
then centrifuged to separate the digestion enzyme and analyzed by LC/MS/MS. LC
separation of the digests were performed on a C18 reverse phase column using water and
ACN as mobile phases with a gradient from 1% ACN to 99% ACN over 80 min.
Data Fitting. HNSB labeling curves were fit with the exponential equation: 𝑌 =
𝑌0 + 𝐴𝑒 𝑘0 𝑥 . Where Y0 is the asymptotic limit, k is the rate, A is a pre-exponential factor,
and x is time.
Activation Energy Calculations. The Arrhenius equation of the form ln 𝑘𝑟 =
𝐸

ln 𝐴 − 𝑅𝑇𝑎 was used to determine the activation energy (𝐸𝑎 ) from the rates of Trp60 burial
at different temperatures. 𝑘𝑟 is the Trp60 burial rate, 𝐴 is the Arrhenius preexponential
factor, 𝑅 is the gas constant, and 𝑇 is the temperature. The Eyring equation of the form
ΔS

E𝑎

k 𝑟 = κe2 Be R e−RT was used to relate activation energy (Ea) to activation entropy (ΔS)
where B =

𝑘𝑇 𝑅𝑇
ℎ 𝑝°

. κ and 𝑝° are each taken to be 1, as is the most common form, and ℎ is

Planck’s constant.
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2.3 Results and Discussion
Upon adding Cu(II),19,21 the extent of β2m labeling by HNSB decreases over time
before leveling off at around 30 min (Figure 2.3). The labeling decrease and leveling off is
consistent with Trp60 being partially, but not fully, buried as Cu(II) causes the CTI of
Pro32.13 β2m has two Trp residues, Trp60 and Trp95, but because Trp95 is more buried,
>90% of the HNSB labeling occurs at Trp60, as determined by proteolysis and LC-MS/MS
(Figure 2.4). Due to the low amount of labeling and lack of labeling change on Trp95,
changes in total Trp labeling in the protein can be used to measure the burial of Trp60.

Figure 2.3: The rate of Trp burial under different conditions as determined by HNSB Trp
labeling. Cu(II) induces the structural change leading to Trp60 burial while Ni and Zn do
not. ΔN6-β2m reacts with HNSB to a lesser extent than wild-type 2m because Trp60 is
more buried in that construct. Experiments were performed at 22 °C with 75 μM 2m in
25 mM MOPS and 150 mM potassium acetate at pH 7.
21

Figure 2.4: Extent of HNSB labeling from proteolytic digestion followed by LC-MS/MS
of β2m, indicating total labeling and labeling at Trp60 from measured peptide Asp59Tyr63 and labeling at Trp95 from measured peptides Trp95-97 and Trp95-Met99.
Without Cu(II), β2m demonstrates no change in Trp60 exposure over more than 6 h. As a
control, the truncated β2m species, ΔN6- β2m, which is missing the first six N-terminal
residues and has a trans Pro32 and thus a more buried Trp60,17,18 was also reacted with
HNSB. As expected, its reactivity is lower than wild type β2m and does not change
significantly over time (Figure 2.3). To ensure that metal binding itself does not affect the
HNSB labeling reaction, β2m was incubated with Ni(II) and Zn(II), which do not promote
amyloidogenesis.25 Trp labeling extents are similar to the metal-free protein, consistent
with no Trp burial over time. Together, these data show that HNSB can be used to monitor
Trp60 burial that coincides with Pro32 CTI.
From a fit of the Cu(II) data in Figure 2.3 using 𝑌 = 𝑌0 + 𝐴𝑒 𝑘0𝑥 , a Trp60 burial
rate of 0.16 ± 0.06 min-1 is determined. This burial rate is about the same when 500 mM
22

Figure 2.5: Extent of HNSB labeling on β2m when incubated with Cu(II) and 500 mM
urea over a 120 min period.
urea is added with Cu(II) (Figure 2.5). This is important as 500 mM urea is often added
during β2m amyloid formation reactions to mimic uremia in dialysis patients and is known
to accelerate β2m amyloid formation in vitro,8–11,21,24,26 so its small effect on the Trp60
burial rate likely indicates an effect later in the amyloidogenesis pathway. Because Trp60
burial is an essential part of the structural change, we propose that the rate of Trp60 burial
is a good proxy of the rate of this amyloidogenic switch.12–16 Consistent with the idea that
Trp60 burial is an indicator of the amyloidogenic structural change is the fact that
thioflavin T (ThT) data indicate amyloid oligomer formation is on a time scale that is
slightly longer than the decrease in Trp60 labeling upon Cu(II) addition (Figure 2.6). A
change in ThT fluorescence is a well-known indicator of protein amyloid formation in
solution,27 yet several studies have shown that ThT’s fluorescence changes as β2m
23

Figure 2.6: Comparison of HNSB Trp labeling data with ThT fluorescence data at 22 °C
when incubated with Cu(II) and 500 mM urea.
oligomers form.20,28,29 β2m oligomers should form after the amyloidogenic structural
change has occurred,10,12–16 and the rate of oligomer formation as revealed by ThT
fluorescence (Figure 2.6) is 0.03 min-1 at 22°C, which, as expected, is slower than the rate
of the amyloidogenic structural change in the presence of Cu(II) at 22°C.
HNSB labeling was also utilized to monitor the structural change initiated by 20%
TFE (Figure 2.7) and acid at pH 3.5 (Figure 2.8).8–11,30 There are stark differences in Trp
labeling profiles as compared to initiation with Cu(II). With TFE, there is a 40-min lag
period before Trp labeling decreases, resulting in a Trp60 burial rate of 0.013 ± 0.003 min-1.
The reason(s) for the lag period is unclear, but it is likely due to some conformational
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Figure 2.7: Trp burial in 2m using HNSB in the presence of 20% TFE at 22 °C. Data
were fit after the 40-min lag period, giving a rate of 0.013 ± 0.003 min-1. Experiments were
conducted with 75 μM 2m in 25 mM MOPS and 150 mM potassium acetate at pH 7.4.

Figure 2.8: HNSB labeling of 2m at pH 3.5 (citrate buffer) at 22 °C. The initial decrease
is due to Trp60 burial, but the sudden increase at 30 min is due to a structural change that
causes the exposure and labeling of Trp95 (see Figure 2.9). Data were fit from 0-20 min
(inset), giving a rate of 0.49 ± 0.05 min-1.
25

change that needs to occur before the CTI of Pro32 can proceed, as the time scale of the
lag is too long to be due to TFE-related solvent effects.31–33 DLS measurements and ThT
fluorescence show no oligomerization for up to 24 h after TFE addition, indicating that the
structural change occurs long before aggregation. These data are the first evidence of TFE
causing the β2m amyloidogenic structural change that is known to occur with Cu(II) and
acid.
Trp labeling has a distinct profile when amyloid formation is initiated at pH 3.5
with a sharp decrease over about 20 min before undergoing a slight increase until around

Figure 2.9: Extent of HNSB labeling on Trp60 and Trp95 over time after initiation with
acid at pH 3.5. These data were obtained from proteolytic digestion followed by LCMS/MS analysis of β2m. Trp labeling at Trp60 is an average of the values from the
following measured peptides Ser55-Trp60, Ser57-Trp60, Ser57-Phe62, and Ser57-Tyr63,
and labeling at Trp95 is an average of the values from the following measured peptides
Ser88-Trp95, Val93-Met99, and Lys94-Met99. The error bars represent one standard
deviation.
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40 min when it levels off and then decreases again (Figure 2.8). This labeling profile is due
to both structural and oligomeric changes in β2m. Proteolytic digestion followed by LCMS/MS analyses indicate that this is a special case in which Trp60 labeling decreases
steadily after the addition of acid, due to the amyloidogenic conformational change, while
Trp95 labeling increases (Figure 2.9). Trp95 is relatively unreactive with HNSB, but over
time at pH 3.5, the protein evidently unfolds to expose Trp95, leading to increased
reactivity. The decrease in Trp60 labeling is on a comparable time scale with β2m
oligomerization, as indicated by DLS and ThT measurements (Figure 2.10), again showing
that Trp60 labeling probes the formation of the amyloid competent state that precedes
oligomer formation. To determine the rate of the structural change, the labeling results were

Figure 2.10: Comparison of CL-MS data with ThT fluorescence and DLS data during the
pre-amyloid structural change. All experiments were conducted with 75 μM 2m at pH
3.5.
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fit for the first 20 min, giving a rate of 0.49 ± 0.05 min-1 at 22 °C. For comparison, the
oligomerization rates as indicated by ThT fluorescence and DLS changes (Figure 2.10) are
0.085 ± 0.001 min-1 and 0.08 ± 0.01 min-1, respectively. These measurements are consistent
with oligomerization occurring after the pre-amyloid structural change.
Activation barriers for the amyloidogenic structural change were determined by
measuring the Trp60 burial rates at different temperatures. As an example, Figure 2.11
shows a comparison of Trp labeling in the presence of Cu(II) at 22C and 37C. At 37C,
the structural change occurs somewhat faster (0.21 ± 0.06 min-1 vs. 0.16 ± 0.06 min-1). The
Arrhenius Equation (Equation 2.1) was used to determine the activation energy barrier and

Figure 2.11: Comparison of the rate of Trp burial at 22 °C and 37 °C for Cu(II) initiated
amyloid reaction. The normalized relative extent of labeling reaches a lower value at 37 °C
primarily because the labeling reaction with HNSB is more extensive at this higher
temperature.
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the preexponential factor and the Eyring Equation (Equation 2.2) were used to relate the
activation energy to the activation entropy of this reaction (Table 2.1).
𝐸

Equation 2.1

ln 𝑘𝑟 = ln 𝐴 − 𝑅𝑇𝑎

Equation 2.2

k 𝑟 = κe2 Be R e−RT

ΔS

E𝑎

Of the conditions tested, the structural change in the presence of Cu(II) has the
lowest activation energy and preexponential factor. The addition of urea with Cu(II) has
little effect on the activation energy. In the presence of 20% TFE, the activation energy is
higher and the frequency factor is several orders of magnitude higher. Despite acid causing
the highest rate of Trp60 burial at 37 °C, the determined energy barrier is the highest of the

Table 2.1: Rates of Trp60 burial, activation energy barriers (Ea), pre-exponential factors
(A), and activation entropies (ΔS) for each amyloid formation condition.
*A lag of ~10 mins is seen prior to Trp60 burial. ** A lag of ~40 mins is seen prior to
Trp60 burial.
ǂThe Eyring equation was used to relate Ea and ΔS.
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three conditions. The high frequency factor associated with the structural change at pH 3.5
explains the apparent disconnect. Clearly, the acid-induced amyloidogenic structural
change is very sensitive to temperature. Indeed, at 37 °C in acid, visual evidence for the
formation of amyloid fibrils occurs within a week, but at 4 °C in acid, no fibrils are
observed for over a year.
CTIs of Pro residues have energy barriers typically ranging between 60 and 100
kJ/mol in peptides and refolding proteins, depending on sequence and other effects.34–37
His residues on the N-terminal side of Pro residues, as is the case in β2m, usually reduce
Pro CTI barriers,38 which likely means the barrier of wild-type β2m is lower than average.
Our measurements indicate that Cu(II) binding leads to an energy barrier for the β2m preamyloid structural change that is much lower than typical CTI values for Pro, suggesting
that Cu(II) binding reduces the Pro32 CTI barrier substantially. Metal cations are known
to catalyze Pro CTI.39,40 Cu(II) binding at His31 in β2m19,41,42 presumably accelerates CTI
at His31-Pro32 because the measured barrier for the conformational change is quite low.
Given the low measured barrier, His31-Pro32 CTI is likely the rate-determining step for
the pre-amyloid structural change in the presence of Cu(II). The measured energy barrier
with TFE is slightly below typical Pro CTI barriers, suggesting that TFE may be
influencing the Pro32 CTI barrier to a small extent. Hydrogen bonds donated by solvents
are known to stabilize both the cis and trans isomers of Pro, increasing the barrier to
isomerization.43 The disrupted hydrogen bonding caused by TFE may have the opposite
effect, destabilizing both isomers and lowering the barrier to Pro32 CTI.
Interestingly, the measured barrier at pH 3.5 is much higher than the typical Pro
CTI activation barriers, even though acid is known to decrease Pro CTI barriers,
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particularly in cases where His precedes the prolyl bond.38 This high barrier for the
amyloidogenic structural change suggests that His31-Pro32 CTI is not the rate-determining
step for the pre-amyloid structural change in the presence of acid. Very likely another
conformational change must occur in addition to His31-Pro32 CTI for β2m to proceed to
form amyloids at pH 3.5. Acidic conditions also give a significantly higher preexponential
factor than the other conditions, which is likely due to the protein rapidly fluctuating
between several partially structured and unfolded states,44 leading to increased
conformational heterogeneity and an increased statistical probability of adopting the higher
energy transition state. In contrast, the preexponential factor with Cu(II) is much lower,
which can be rationalized by the tight transition state that is almost certainly imposed by
Cu(II) coordination to the N-terminal amine, the Ile1-Gln2 backbone amide, His31, and
Asp59,19,40 which span a significant portion of the protein sequence. It is remarkable that
β2m is capable of forming amyloid fibrils under conditions that have such distinct effects
on the structure of the monomer.
2.4 Conclusions
To our knowledge, the results described here represent the first-ever measurements
of energetic barriers for the structural change that initiates protein amyloid formation.
These measurements yield new biochemical insight, specifically for β2m. Such
measurements have great potential for further elucidating the mechanistic details of β2m
amyloid formation. In future work, we will measure the activation barriers for various
mutants of β2m as a means of revealing the specific structural features that control the preamyloid structural change. One could also envision using the Trp labeling reaction to
screen for molecules that prevent the pre-amyloid structural change. More generally
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speaking, because protein amyloidosis is typically triggered by large structural changes,
CL-MS should be useful for measuring unfolding barriers for other amyloid systems where
the burial or exposure of specific residues can be monitored over time to yield kinetic and
energetic information.
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CHAPTER 3
PRIMARY AND SECONDARY NUCLEATION MEDIATED PROTEINPROTEIN INTERACTIONS FOR INITIATION OF A PRE-AMYLOID
STRUCTURAL CHANGE
3.1 Introduction
Amyloid forming protein systems involve complex assembly mechanisms that lead
to aggregation and eventual amyloid formation. Due to this complexity, little is still known
about the mechanisms and energetics of assembly. Most amyloidogenesis, including that
of β-2-microglobulin (β2m), is a nucleation dependent process. Two types of nucleation
have been identified in amyloid formation: primary nucleation and secondary nucleation.
Primary nucleation occurs when monomeric species interact, causing a changing in
structure that leads to aggregation and amyloid formation. A hallmark of primary
nucleation is a lag phase after mixing that precedes oligomerization. Secondary nucleation
occurs when pre-formed oligomeric species or fibrils are present, allowing free monomers
to template from them, causing continued aggregation. Under secondary nucleation, an
elimination of the lag phase is seen, allowing the growth phase to proceed immediately.
Secondary nucleation is commonly taken advantage of to shorten fibril growth times
through the use of oligomeric seeds.1–11 Amyloid seeds are metastable oligomeric species
that are created from pre-formed amyloid fibrils. There are several ways they can be formed
from fibrils including sonication, chemically, freeze-thawing, and homogenates of amyloid
containing tissue, as well as combinations of techniques. Sonication is the most commonly
used method for in vitro seed generation.5–7,11–28 The metastability of amyloid seeds
requires their rapid use after formation before they begin to reaggregate into fibrils.
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Both primary and secondary nucleation have been identified in several amyloid
systems, including amyloid-β (Aβ),29,30 insulin,31 islet amyloid polypeptide (IAPP),32 αsynuclein,33,34 and carbonic anhydrase.35 Primary nucleation occurs when monomers
dominate in solution, but secondary nucleation occurs when enough aggregates have
formed or seeds are added to interact with the monomers. In all such systems, secondary
nucleation creates a catalytic feedback that results in amplification of amyloid aggregation.
The rate of aggregation for primary nucleation mechanisms depends on monomer
concentration, while the rate of aggregation for secondary nucleation mechanisms depends
on aggregate or seed concentration.1 One group has recently determined activation energy
barriers to fibril elongation for both primary and secondary nucleated versions of the Aβ
amyloid forming process.4 This work has inspired us to investigate energy barriers to
primary and secondary nucleation dependent amyloidosis in β2m.
Primary and secondary nucleation in β2m amyloidogenesis has been investigated
previously by the Radford group. For example, under the primary nucleation mechanism,
they determined that the addition of certain glycosaminoglycans (GAGs) resulted in
spontaneous amyloid growth by stabilizing rare and transient aggregates.36 Through NMR
studies, the Radford group was also able to characterize interactions inhibiting or
promoting amyloid formation under primary nucleation by demonstrating that interactions
between ΔN6-β2m and human WT β2m creates a productive structural change in WT β2m,
while interactions between ΔN6-β2m and murine WT β2m (mβ2m) leads to kinetically
trapped dimers.37 Using ion mobility-MS and electron microscopy, the Radford group
showed, that at low pH and under primary nucleation conditions, rapid interconversion
between oligomeric species leading to short, curved fibrils that can be stabilized at high
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ionic strength.38 The secondary nucleation mechanism was probed by another comparison
between human WT β2m and mβ2m, in which they demonstrated the importance of
solubility of the protein and ionic strength of the solution during seeded amyloidosis. Much
of the work on this topic has been done using a comparison between primary and secondary
nucleation to reveal new information about β2m amyloidosis. Through this comparison
they have been able to determine important regions of interaction for fibril formation (e.g.
residues 62-70),7 suggest physiological factors in synovial fluid that stabilize seeds in
vivo,18 show that ionic strength and population of different intermediates leads to differing
fibril morphology,40 and how amyloid inhibitors work by binding monomers and diverting
them off pathway.41 The Radford group has also used comparisons of primary and
secondary nucleation mechanisms using ΔN6-β2m to demonstrate that trans Pro32 is
critical to amyloidosis and that ΔN6-β2m can convert WT β2m to an amyloid competent
state through transient head-to-head dimers.10,42 Once aggregation has begun, molecular
shedding from fibrils and seeds yield toxic oligomers at pH 6.4, but non-toxic native
monomers at pH 7.4.43 However, even through all this work, many of the molecular
interactions occurring during primary and secondary nucleation are not well understood.
In this work, we have focused on primary and secondary nucleation dependent
amyloidogenesis between WT β2m and an amyloidogenic variant ΔN6-β2m. ΔN6-β2m is
a naturally occurring truncation of β2m missing the first 6 N-terminal amino acids.44 These
6 amino acids play a key role in preserving the cis conformation of the Pro32 in WT β2m.
Disruption of the interactions between this N-terminal strand and the His31-Pro32 amide
bond, or removal of this six-residue strand, allows for the Pro32 to adopt the trans
conformation. ΔN6-β2m has a trans-locked Pro32 and is naturally amyloidogenic.
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Interestingly, not only can ΔN6-β2m spontaneously form amyloids, it has also been shown
to interact with WT β2m and induce the pre-amyloid structural change characterized by
the cis-trans isomerization (CTI) of His31-Pro32, thereby causing amyloidogenesis in WT
β2m in a prion-like manner.45,46 Based on NMR experiments, Karamanos, et al have
proposed a transient head-to-head interaction between the two proteins that induces the
pre-amyloid structural change in the WT.37 This interaction involves several loops at the
‘head’ of the proteins, the end of the protein closest to the N-terminus that includes the BC,
DE, and FG loops (Figure 3.1). This part of the protein contains not only the important
H31 and Pro32 residues, but Trp60 and the N-terminal strand of WT as well. The goal of

Figure 3.1: The head of the β2m protein comprised of the N-terminus (green strand),
the BC loop (blue) including His31, the DE loop (yellow) including Trp60, and the FG
loop (orange).
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this work is to determine the energy barriers of the primary and secondary nucleation steps
of WT β2m as induced by ΔN6-β2m. Further experiments endeavor to determine essential
interactions between these two proteins in both the primary and secondary nucleation cases
by studying what structural factors influence the CTI rates and energy barriers.
3.2 Experimental
Covalent labeling-mass spectrometry (CL-MS) was used in the same manner as in
Chapter 2. The labeling reagent dimethyl(2-hydroxy-5-nitrobenzyl) sulfonium bromide
(HNSB) was used to covalently label solvent accessible Trp residues in both WT and ΔN6β2m. For these experiments, labeling, quenching, and injection were automated. An
Agilent 1100 G1367A well plate autosampler was reprogrammed to perform all liquid
handling portions of the experiment, from mixing of protein samples, to reacting with
HNSB, to quenching with L-Trp, to injection on a desalting column (See Appendix). This
setup includes tight temperature control of the samples within the well plate autosampler.
Immediately after desalting, samples were analyzed on a Bruker SolariX FT-ICR mass
spectrometer.
For primary nucleation experiments, ΔN6-β2m was incubated with WT β2m in a
3:1 (ΔN6:WT) ratio. At different time points, the proteins were reacted with HNSB for 45
seconds. The reaction was then quenched with the addition of L-Trp and the sample
immediately desalted and analyzed. This process was repeated at different temperatures of
incubation and the data analyzed in the same way as in Chapter 2. These primary nucleation
experiments were also performed in the same manner by incubating the H31F mutant of
β2m with ΔN6-β2m in the same ratio.
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For secondary nucleation experiments, ΔN6-β2m was incubated at 37°C buffered
to pH 6.2 until the formation of aggregates that could be seen by eye (usually 5-9 days).
Seeds were then generated by sonication of the aggregate for 5 min. Any remaining solid
was pelleted at the bottom of the tube by centrifugation and the supernatant removed and
filtered with a 0.45 μm syringe filter. It is critical that the resulting amyloid seed solution
be used immediately after filtration. The seed solution was then added to monomeric WT
β2m at either pH 7.4 or 6.2 for differing incubation times using the same Agilent HPLC
setup as the primary nucleation experiments and analyzed in the same way.
The primary nucleation reaction was also monitored by size exclusion
chromatography (SEC), dynamic light scattering (DLS), and native MS to observe what, if
any, oligomeric species might be present at different points during the reactions and the
nature of these oligomeric species. SEC was performed by injection of the reaction mixture
onto a size exclusion column at various time points after mixing ΔN6-β2m with WT. DLS
was performed by constant measurements of the sample for up to 12 hours at different
temperatures. Prior to performing native MS, each sample was rapidly desalted before
analysis on a Waters Synapt G2Si.
3.3 Results and Discussion
When ΔN6-β2m and WT β2m are incubated at a 3:1 ratio, Trp labeling with HNSB
shows an unexpected increase in labeling on WT before the extent of Trp labeling drops in
a manner consistent with previously seen data reflecting CTI of Pro32 (see Chapter 2). The
time of this increase in labeling is temperature dependent and likely reflects some other
structural rearrangement that must occur during the lag phase prior to the pre-amyloid
structural change. For example, the increase in labeling occurs over 1 h at 40°C, 2 h at
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Figure 3.2: Extent of HNSB covalent labeling on wild-type (WT) β2m when incubated
with ΔN6-β2m at a 3:1 ratio (ΔN6:WT)
37°C, and 3 h at 35°C. It is unclear what this other structural rearrangement might be, and
further experimentation will be needed to ascertain its nature. Trp labeling data were fit
from the end of the HNSB labeling rise (beginning of the labeling drop) using the same
method as in Chapter 2. At 40°C, this corresponds to a fit from 1 h to 8 h, giving a rate of
0.32 ± 0.06 hr-1 or 0.005 ± 0.001 min-1 (Figure 3.2). The experiment was repeated at 37°C
and 35°C and data fit (after the increase in labeling) in the same manner. The Arrhenius
Equation (Equation 3.1) was used to determine the activation energy barrier and the
preexponential factor and the Eyring Equation (Equation 3.2) was used to relate the
activation energy to the activation entropy of this primary nucleation reaction.
Equation 3.1

𝐸

ln 𝑘𝑟 = ln 𝐴 − 𝑅𝑇𝑎
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ΔS

Equation 3.2

E𝑎

k 𝑟 = κe2 Be R e−RT

In comparison to most of the previously measured energy barriers for this cis-trans
Pro32 isomerization, the ΔN6/WT monomeric coincubation shows a very high barrier of
136 ± 32 kJ/mol (Table 3.1).47 This barrier is higher than the range that is typically expected
from cis-trans Pro isomerizations (60-100 kJ/mol).48–51 The only other condition
previously measured that shows similar Arrhenius parameters is the amyloidogenesis of

Table 3.2: Rates of Trp60 burial, activation energy barriers (Ea), pre-exponential factors
(A), and activation entropies (ΔS) for each amyloid formation condition.
*A lag of ~10 mins is seen prior to Trp60 burial. ** A lag of ~40 mins is seen prior to
Trp60 burial. ǂThe Eyring equation was used to relate Ea and ΔS.
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WT β2m as induced by acid. We have previously hypothesized that the unexpectedly high
energy barrier seen in the acid induced case may indicate that the cis-trans Pro32
isomerization is not the rate determining step under those conditions. Due to the similarity
in Arrhenius parameters, it is possible that the CTI is also not the rate determining step in
the primary nucleation mechanism between ΔN6-β2m and WT β2m. This speculation is
supported by the presence of the other structural change preceding the CTI, the nature of
which has yet to be determined.
In an effort to determine what oligomeric species might be present during the β2m
structural change that is measured, the β2m/ΔN6-β2m sample was also monitored by SEC,
DLS, and native MS. The purpose of these experiments was to confirm if monomermonomer interactions between ΔN6-β2m and WT are responsible for initiating the preamyloid structural change or some other stoichiometry of the protein complex. Insight here
may also suggest possibilities of the nature of the structural change that occurs before the
CTI that gives rise to an increase in Trp labeling. SEC, DLS and native MS reveal that
when ΔN6-β2m and WT are incubated together (3:1 ratio) at 40°C, formation of complexes
and aggregates is seen more rapidly than expected. By SEC, we see a sudden sharp drop in
the area under the curve of all species present, indicating a loss of concentration of the

Figure 3.3: Coincubation of ΔN6-β2m and WT β2m at 40°C probed by a) Size exclusion
chromatography (SEC) of the monomer peak, b) Dynamic light scattering (DLS), and c)
Total ion intensity from ESI mass spectrometry measurements
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proteins likely caused by aggregates dropping out of solution (Figure 3.3a). The
precipitation of the aggregates coincides in time with the peak of the HNSB labeling data,
where it begins to drop in a manner consistent with CTI of Pro32. DLS performed at 40°C
shows the rapid evolution of very large aggregate species (up to ~1400 nm) followed by a
sudden drop indicative of these large species precipitating out of solution (Figure 3.3b),
further supporting what is seen by SEC. These appear to be amorphous aggregates as they
are able to be solubilized by sodium dodecyl sulfate (SDS) indicating they may be offpathway aggregates. Both SEC and DLS show these phenomena in a temperature
dependent manner similar to HNSB labeling. The timing of the aggregation and
precipitation shown by SEC and DLS shifts to match the timing of the peak and subsequent
drop in HNSB labeling at each temperature measured. Additionally, ESI-MS
measurements show a drop in total intensity of the WT peaks, at the same time period,
further indicating aggregation (Figure 3.3c). The agreement between all these techniques
leads us to believe that the formation of these aggregates prior to the amyloidogenic
structural change are likely involved in changing the structure of WT β2m in some way,
leading to the increase seen in HNSB labeling. Native MS experiments were also done to
more closely observe the species that remain soluble in the system. After the drop seen

Figure 3.4: Native MS spectrum of a coincubation of ΔN6-β2m and WT β2m showing all
three possible dimers, as well as larger, unidentified species.
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with the other techniques, native MS shows peaks corresponding to monomeric ΔN6-β2m
and monomeric WT β2m, as well as ΔN6-β2m homodimers, WT homodimers and
ΔN6/WT heterodimers (Figure 3.4). Larger species were also observed that will require
further experimentation to identify. These observations may indicate that the dimers
observed or larger species that are observed, including precipitated aggregates, could be
involved in the structural changes occurring to monomeric WT β2m. At this time, more
experiments are needed to identify these potential interactions.
Other experiments were performed to elucidate some mechanistic information
about the interaction between monomeric ΔN6-β2m and WT β2m leading to
amyloidogenesis. First, the 40°C coincubation experiment was performed at pH 5, 6.2, and
8. These different solution pHs change the charge on His residues of both proteins (4 in

Figure 3.5: Extent of HNSB labeling on WT β2m when incubated at 40°C with ΔN6 at
pH 5, 6.2, or 8.
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each protein). His31 is an important residue because positively charged His residues on the
N-terminal side of Pro residues is known to greatly speed up Pro CTI.52 His31 is also on
the BC loop which is part of the region of the proteins that are proposed to be part of the
interaction site and could cause some repulsion when charged (Figure 3.1).37 His51 is not
involved in the pre-amyloid structural change, but may become an important part of the
interface between monomer units as oligomers form.53 As shown in Figure 3.5, at pH 8
there is no decrease in Trp labeling over 8 hours, while a significant decrease is seen at pH
6.2. This lack of labeling change is unsurprising as ΔN6-β2m is known to lose its
amyloidogenic properties at pH ≥ 8.42 Eichner et al. show that this is due to a complete
suppression of the normally enhanced local dynamics of the BC and DE loops in ΔN6-β2m
at pH ≥ 8.42 At pH 5, when all the His residues will be positively charged, a long drawnout increase in Trp labeling is seen for 5 hours (compared to 1 hour at pH 6.2). The Trp
labeling then begins to drop again, but data needs to be acquired at longer time points to
determine the rate of this decrease. The data at different pHs suggest that the potential
structural change seen prior to CTI may involve interaction between the two proteins as a
longer rise time may indicate some repulsion between key areas of the two proteins.
Targeted point mutations can be valuable to create directed changes to the charge,
bulk, or hydrophobicity of certain regions in a protein. To this end, an H31F point mutant
of β2m was incubated with ΔN6-β2m at pH 6.2 and 40°C in place of WT. Preliminary data
indicate that while the increase in labeling during the lag period appears to be consistent
with the WT, the rate of Trp labeling decrease is slightly, but not significantly, reduced
when the H31F mutation is present (0.005 ± 0.001 min-1 with WT vs ~0.004 min-1 with
H31F). This similarity in rates is further evidence that the CTI of Pro32 may not be the rate
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determining step in the primary nucleation dependent reaction. While the measured rate at
40°C decreases with the H31F mutation, it is not significantly different. If it were the rate
determining step, we would expect a significant change in the measured rate.
Amyloid seeding was used to examine the secondary nucleation dependent
amyloidogenesis of β2m. Amyloid seeds were generated by sonication from ΔN6-β2m
aggregates formed at pH 6.2. HNSB Trp labeling was also used here to monitor the Pro32
CTI of WT β2m when induced by seeds. When seeded at pH 6.2, no decrease in Trp
labeling is seen. However, when seeding occurs at pH 7.4, Trp labeling decreases
immediately, with the lag phase eliminated (Figure 3.6). From two different temperatures
of incubation, we were able to calculate a preliminary energy barrier of ~15 kJ/mol (Table
3.1). More experiments at different temperatures should be performed to get a more

Figure 3.6: Extent of HNSB labeling on WT β2m when incubated with amyloid seeds
generated from fresh ΔN6-β2m aggregates or old ΔN6-β2m aggregates.
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accurate activation energy. It is important to note that no ΔN6-β2m peaks are observed in
the mass spectra for these experiments, indicating that there is no monomer shedding
occurring from the ΔN6-β2m seeds. In contrast to the acid induced and ΔN6-β2m induced
primary nucleation cases, the Arrhenius parameters of the seed induced pre-amyloid
conversion are much more consistent with Pro32 CTI being the rate determining step (as
in the Cu(II) and TFE induced cases) (Table 3.1). In fact, the Arrhenius parameters match
very closely to those of the Cu(II) induced case, indicating that, like Cu(II), the seeds are
substantially lowering the Pro32 CTI barrier and are likely acting in a catalytic manner in
the process. The specifics of how these seeds are interacting with β2m monomers has yet
to be determined. Also, in contrast to the primary nucleation experiment, the soluble
concentration of WT β2m remains constant over the period of the experiment. While pH
of seeding seems critical to the amyloidogenic success of the reaction, the age of the
aggregates from which the seeds are formed also plays a role. Seeds from ‘fresh’ aggregate
(5-9 days of incubation) show different results from seeds formed from months-old
aggregate (Figure 3.6). Seeds formed from older aggregates give a different rate of labeling
change as well as a much higher error, perhaps indicating a more dynamic, heterogeneous
system.
The seeding reactions were also done with two separate preparations of ΔN6-β2m,
expressed and purified by two different people several years apart. One of the preparations
contained as yet unidentified impurities. The preparation with the impurities did not yield
seeding competent aggregates. This indicates that there may be some interference from
these impurities inhibiting the secondary nucleation mechanism. Further investigation will
be required to identify these impurities (Figure 3.7).
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Figure 3.7: Extent of HNSB labeling on WT β2m when incubated with amyloid seeds
generated from a ΔN6-β2m preparation with impurities or a ΔN6-β2m preparation without
impurities.
As stated previously, the primary (soluble ΔN6-β2m) and secondary (ΔN6-β2m
seeds) nucleated conversion of WT β2m show very different activation energy barriers.
This difference is expected as seeding is commonly used in amyloid research to speed
aggregation. The catalytic way in which seeds interact with monomeric WT β2m
drastically lowers the energy barrier to CTI of Pro32. This also has the effect of removing
the lag phase that is commonly seen when two monomeric amyloidogenic proteins interact.
The results here are consistent with what has been seen for primary and secondary
nucleation in the Aβ system. Our measurements differ, however, from what has been
reported with the temperature dependence of the Aβ secondary nucleation reaction. Cohen
et al. have shown that the rate increases with increase in temperature in the primary
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nucleation mechanism but decreases with increasing temperature in the secondary
nucleation mechanism.4 Our work shows the rate increasing with increasing temperature
for both primary and secondary nucleation. While these are both amyloid forming systems,
it should be noted that there are several important differences between how the systems
undergo amyloidogenesis. β2m undergoes a distinct conformational change gated by a CTI
of Pro, whereas Aβ is not known to have such a conversion. This difference may explain
the differences in thermodynamics of the secondary nucleation mechanism. However, as
mentioned, β2m does maintain the lag phase in primary nucleation and has no lag phase in
secondary nucleation, which is consistent among amyloid systems.
3.4 Conclusions and Future Work
Our work has shown that there are two distinct mechanisms for the induction of the
pre-amyloid structural change as initiated by ΔN6-β2m. The primary nucleation
mechanism is consistent with primary nucleation in other amyloid systems in terms of
thermodynamics and the presence of the lag phase seen before amyloidogenesis. We
determined the activation energy barrier of the primary nucleation reaction to be 136 ±
32 kJ/mol. This energy barrier is quite high and out of the range of typical Pro CTIs. This
high barrier makes it likely that the CTI of Pro32 is no longer the rate determining step
when ΔN6-β2m is used to induce amyloid formation. We have also identified the presence
of another structural change that seems to occur causing the CTI of Pro32 to no longer be
the rate determining step of the reaction. Future work should be focused on determining
what this other structural change is and how it affects the amyloid forming process.
Specifically, CL-MS with a more promiscuous reagent and/or hydrogen-deuterium
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exchange (HDX)-MS may be needed to uncover what part of the protein’s structure is
changing.
A large sudden drop in the concentration of the soluble monomeric WT β2m was
identified by MS. This concentration drop coincides in time with the rise in HNSB Trp
labeling during the lag phase before the drop in labeling associated with the Pro32 CTI.
SEC and DLS measurements reveal a rapid aggregation of large species that then
precipitate out of solution. Native MS experiments show the quick evolution of all three
possible dimer species: the ΔN6-β2m homodimer, the WT β2m homodimer, and the
ΔN6/WT heterodimer. Also seen in native MS are larger species that have not yet been
identified. Future experiments should focus on identification of the larger species seen and
determining which species are involved in inducing the pre-amyloid structural change in
the WT. Further native MS experiments, including ion mobility measurements would be
useful for identifying these larger species. In addition, after the rapid aggregation, the
precipitate and supernatant should be separated from each other and each mixed with fresh
monomeric WT β2m to determine if it is truly monomeric ΔN6-β2m inducing the preamyloid structural change in the WT or if it is the evolution of the larger species that
induces this change.
The charge on each protein was revealed to be critical by changing the pH of the
reaction. At pH 8, all amyloidogenicity is lost, consistent with the suppression of enhanced
dynamics of the BC and DE loops in ΔN6-β2m resulting in the loss of amyloidogenicity.42
At pH 5, the lag phase is lengthened, further indicating that this lag phase may be associated
with a structural change at the beginning of the ΔN6/WT interaction. At this pH, the His
residues in the proteins would be charged, leading to some repulsion between the critical
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head regions. Future work should include longer time points at pH 5 to see if, once the Trp
labeling begins to drop, there is any change in the rate of Pro32 CTI. It may also be
interesting to see what happens to the lag phase at pH 3.5, as WT β2m is known to be
amyloidogenic at this pH.
We have also added evidence that the CTI of Pro32 may not be the rate determining
step in the primary nucleation mechanism with ΔN6-β2m via studies of the point mutant
H31F. Even though H31 has been shown to be important to the CTI of Pro32, its
replacement does not drop the rate significantly as it should do for a rate determining CTI
of Pro. Future work should repeat the ΔN6/H31F coincubations at different temperatures
to elucidate an activation energy barrier for comparison with ΔN6/WT. Other point mutants
should also be incubated with ΔN6-β2m to find their mechanistic effects. An H51F mutant
would help determine if the species contributing to the induction of the pre-amyloid
structural change are indeed monomeric or if they are some larger species because H51 is
in a region of the protein involved in oligomerization.53 If the rate is unaffected by the
H51F mutation, that would be more evidence of a true monomer-monomer interaction
between ΔN6-β2m and WT β2m. If the rate is greatly reduced by H51F, that may indicate
a larger oligomeric species is involved in inducing the pre-amyloid structural change in
WT. Another mutation of critical interest is R3A. The charged sidechain guanidinium
group of Arg3 points at the H31-P32 bond and has significant electrostatic interactions that
help stabilize the Pro32 in the cis conformation. Replacement of this Arg3 with an Ala
should greatly reduce the energy needed to initiate the CTI. This change would also swap
a large sidechain for a much smaller sidechain in the head region of the protein where WT
β2m interacts with ΔN6-β2m. Additional mutants of interest are F30A, which would swap
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a bulky sidechain for a small side chain in the head region of the protein while remaining
hydrophobic and uncharged, and F62A for the same reason, but on a different loop in the
head region of the protein. The F30A mutant is interesting because an important step in the
cascade of events leading to aggregation of WT β2m when initiated by Cu(II) is the rotation
and subsequent exposure of Phe30 out of the hydrophobic core.54 However, the interaction
between WT β2m and ΔN6-β2m stabilizes residues on the BC loop that contains Phe30.42
Use of the F30A mutant could give insight as to the importance of the Phe30 in the WT
β2m/ΔN6-β2m interaction. If this residue is as important to this process as it is to the Cu(II)
induced aggregation, there would be a significant change in HNSB labeling. Phe62 is on
the more dynamic DE loop which is implicated in the interaction between WT β2m and
ΔN6-β2m.42 If the reduction in bulk on this loop in the F62A mutant allows for increased
interaction between WT β2m and ΔN6-β2m, it would result in a higher measured Pro32
CTI rate for this process. The use of these two point mutants would be helpful for
investigating these necessary molecular interactions during the ΔN6-β2m initiated
amyloidosis of WT β2m while controlling for charge and hydrophobicity.
The secondary nucleation mechanism is consistent with secondary nucleation in
other amyloid systems in that the lag phase does not occur. The pre-amyloid structural
change occurs directly and without any evidence of other structural changes happening
first. The interaction between amyloid seeds and monomeric WT β2m appears catalytic in
nature and greatly reduces the activation energy barrier. The activation barrier falls into a
range that would indicate that, in contrast to the primary nucleation mechanism, the Pro32
CTI is the rate determining step. Charge is again critical here as seeding competency is
removed when the pH is raised from 6.2 to 7.4. This pH effect may indicate that, while
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charge on His residues is a hindrance in the primary nucleation reaction, charged His
residues are required for the interaction between monomers and seeds. Future experiments
should include a wider range of pHs to better understand this phenomenon. The ‘freshness’
of the seeds is also important as the rate changes when older seeds are used. Further work
is needed to ascertain why this is the case. Finally, the seeding solutions are likely
composed of a distribution of differently sized species. SEC, DLS, or ion mobility
experiments are needed here to better characterize the species involved in inducing the preamyloid structural change.
Of two ΔN6-β2m preparations used, one contained impurities that appeared to
hinder seeding. These impurities do not seem to inhibit the primary nucleation mechanism,
but only the secondary nucleation mechanism. When these impurities are present, the
ability for the seeds to induce the pre-amyloid structural change in monomeric WT β2m is
completely removed. At this time, the identity of these impurities is unclear. Future work
should be focused on identifying these impurities and how they inhibit the seeding process.
These future studies would give interesting insight into the mechanisms of seeding and the
molecular factors that interfere with that process. This insight could lead to the ability to
design inhibitors for the secondary nucleation mediated amyloidosis process.
Other future work could include seeding experiments done with some of the
mutants of β2m mentioned above. Using different mutants would be a good way to narrow
down what regions of the protein may be interacting with the seed in the secondary
nucleation dependent reaction. Seeding experiments should also be performed with seeds
generated from WT aggregation in order to determine differences (if any) between the
seeding propensity of WT and ΔN6-β2m. These seeding experiments can be accomplished
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both through acid generated WT aggregates and Cu(II) generated WT aggregates using a
Met0 version of WT. Using both methods of generation for WT seeds would reveal if the
seeds created are morphologically different and if that difference affects the seeding ability.
The M0WT would also allow us to see if any monomer shedding from the seeds occur
during the experiment; though this is unlikely as we do not see any monomer shedding
from the ΔN6-β2m seeds.
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CHAPTER 4
SUMMARY AND FUTURE OUTLOOK
4.1 Summary
A mass spectrometry (MS) and covalent labeling (CL) method has been developed
to monitor the burial status of Trp60 in β-2-microglobulin (β2m) and, by proxy, the cistrans isomerization (CTI) of Pro32 that initiates amyloid formation. This technique takes
advantage of the Trp specificity of labeling reagent dimethyl(2-hydroxy-5-nitrobenzyl)
sulfonium bromide (HNSB) and is straightforward enough to be applied broadly in many
different amyloid-forming solution conditions. It has been demonstrated that this method
can be automated through the repurposing of an autosampler and HPLC-MS system,
allowing for higher throughput and more consistent experimentation.
Through method development it has become clear that each new solution condition
investigated may require slight tweaking of the method. For example, under acidic
conditions, the labeling efficiency of the HNSB reaction is reduced, requiring higher
concentrations and/or longer labeling times. For each new experimental condition, it is
important to confirm the HNSB labeling sites and even more critically, ensure that only
Trp60 is changing over time. Whether the experiment is monitoring the movement of one
or more Trp residues at a time becomes obvious from deviations from the standard labeling
curve profile and can be confirmed by proteolytic digestion and LC-MS/MS. Dynamics of
the system being investigated can make data analysis more complicated and may require
more experimentation. For example, in the case of acid induced β2m amyloid formation,
the high dynamic nature requires that many more time points, much closer together, are
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run compared to the Cu(II) induced condition. The high dynamics also require more
replicates to be performed to weed out any outliers and narrow in on the true rate of CTI.
Overall, the developed HNSB CL method is a relatively simple and straightforward way
to quickly gain structural insight into the pre-amyloid structural change of β2m. It can also
be used as a quick and easy ‘first pass’ to identify systems warranting closer investigation.
It would be easy to adapt the automation (using the autosampler) to other CL techniques
that don’t require proteolytic digestion for analysis.
In a published work, we have applied this technique to investigate the molecular
factors governing the activation energy barrier to the CTI of Pro32 in the β2m amyloid
forming process. Energy barriers were determined for the process as induced by Cu(II),
trifluoroethanol (TFE), and acid. The catalytic nature of Cu(II) lowers the energy barrier
substantially and does not appear to be affected by the use of urea, a common additive in
amyloid fibril growth.1–7 This is likely due to the Cu(II) binding close to Pro32 as metal
ions are known to catalyze Pro CTIs.8,9 It is likely, given the low energy barrier, that the
CTI of Pro32 is the rate determining step in this process. While TFE lowers the energy
barrier from a typical Pro CTI barrier, it does so significantly less than Cu(II). The donation
of hydrogen bonds from TFE surrounding the protein likely stabilizes both the cis and trans
conformation of Pro32, increasing the isomerization barrier.10 The energy barrier is
lowered enough that the CTI of Pro32 is still likely the rate determining step in this case.
When initiated by acid, the measured rates are very high and yet, the massive temperature
dependence of the pre-amyloid structural change under this condition yields a very high
activation energy. This high activation barrier may be an indication that the CTI of Pro32
is no longer the rate determining step in this process. Having a different rate-determining
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step would be more consistent with the fact that charged His residues on the N-terminal
side of Pro resides (as His31 would be in this case) are known to greatly reduce the energy
barrier to isomerization.11 The activation energy barrier measurements under these three
solution conditions represent some of the first for amyloid systems and, to our knowledge,
the first of a structural change leading to amyloid formation. The new biological insights
discovered here are valuable for future determination of the mechanistic details of β2m
amyloidogenesis. These results are also a demonstration of how CL-MS can be a useful
tool for measuring energy barriers for other amyloid systems that are triggered by large
structural changes.
The Trp labeling technique developed here was also used to investigate the primary
and secondary nucleation mediated mechanisms of β2m amyloid formation as induced by
the amyloidogenic variant ΔN6-β2m. The activation energy barrier was determined for the
primary nucleation mediated mechanism. The height of this barrier seems to indicate that
in this condition (like that of the previously mentioned acid induced condition) the Pro32
CTI may not be the rate determining step. The use of an H31F mutant in place of wild type
(WT) β2m is further evidence of this conclusion, as the measured rate is not significantly
changed by this mutation. If the CTI of Pro32 were the rate determining step in this
reaction, we would expect a significant difference in rate due to the substitution of a bulky,
uncharged residue for His on the N-terminal side of Pro32. In addition, we have discovered
a rise in HNSB Trp labeling, seen before the drop in labeling characterizing the Pro32 CTI,
that indicates the presence of another structural change during this lag phase. What this
structural change could be is still unclear but appears to be temperature and pH dependent.
It is unlikely to involve the Pro32 CTI as it is unaffected by the H31F mutation. This
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increase in HNSB labeling also coincides in time with a drop in soluble WT and rapid
accumulation of amorphous aggregates as seen by MS, size exclusion chromatography
(SEC), and dynamic light scattering (DLS). The extent of involvement of these aggregates
in the process has yet to be determined.
The secondary nucleation mediated mechanism was probed by amyloid seeding
using seeds generated from ΔN6-β2m. These seeds exhibited a catalytic-like effect,
yielding a large drop in the Pro32 CTI activation energy barrier. The Arrhenius parameters
for this reaction, similar to those of the Cu(II) induced amyloidogenesis, indicate that the
Pro32 CTI is likely the rate determining step. In addition, under seeding conditions, there
is no longer a lag phase seen, consistent with the differences between primary and
secondary nucleation seen in other amyloid systems.12 β2m appears to differ from the
amyloid-β (Aβ) amyloid system in that Aβ exhibits an inverse relationship between
temperature and rate under secondary nucleation, whereas β2m shows a correlation
between rising temperature and rising rate. It also seems that pH changes can impede
seeding competency as successful seeding is seen at pH 7.4, but not at pH 6.2. Interestingly,
as-of-yet unidentified impurities in one of two ΔN6-β2m preparations used, possess the
ability to inhibit the seeding of WT β2m. These impurities do not affect the energy barrier
of the primary nucleation mechanism, but may length the lag period in this process.
These projects together have given new insight into the energetics of β2m
amyloidosis. We have specifically gained new understanding of the mechanism of the
Pro32 CTI leading to amyloid formation and the molecular factors governing it. Different
conditions leading to amyloidosis can be investigated in the future to continue to further
this understanding. A deeper understanding of these factors can aid in finding new methods
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to manipulate and eventually inhibit amyloidosis of not only β2m, but amyloid systems
generally. To this end, β2m can be seen as a model system for the determination of
activation energy barriers leading to amyloid formation. The techniques developed in this
dissertation also demonstrate the capability of CL-MS to measure these barriers, especially
in cases where a large structural change triggers amyloidosis.
4.2 Future Directions
The relative ease and simplicity of the developed CL-MS technique could be
applied to several additional analyses. Good candidates for investigation using this
technique include: amyloid inhibitors and their effect on the CTI of Pro32, the interaction
between amyloidogenic mutant D76N-β2m and WT β2m, seeding amyloidosis with
peptide fragments of β2m, and cross-seeding β2m amyloidosis with other amyloid systems.
These would also all be compatible with automation using the autosampler setup. This
would help gain even further insight into the mechanism of β2m amyloidosis, particularly
the biochemical factors governing the CTI of Pro32.
Several small molecule amyloid inhibitors have been developed for specific
amyloid systems and broadly applicable inhibitors that can act on many amyloid
systems.13–18 Doxycycline, rifamycin and, epigallocatechin-3-gallate (EGCG) have been
demonstrated as small molecule inhibitors of β2m amyloid formation that are able to bind
to the WT β2m monomer.14,19,20 However, the exact mechanism of inhibition is still not
completely clear. Our method is uniquely suited to determine whether the inhibiting
molecules act by preventing the CTI of Pro32. In fact, preliminary data indicates that these
molecules seem to inhibit the CTI process at least up to 120 mins after incubation with
Cu(II), while small molecule binding control suramin slows the onset of, but does not
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inhibit this structural change (Figure 4.1). Further investigation is required to determine
the extent of this inhibition. EGCG in particular seems to induce some structural change in
the monomer as evidenced by the increase in Trp labeling over 120 mins. As we already
have evidence that some molecular factors can inhibit the secondary nucleation mechanism
of β2m amyloidosis but not the primary nucleation mechanism, it would be interesting to
evaluate whether these small molecules can inhibit both mechanisms or just one. These
experiments would be relatively simple to investigate with the ΔN6-β2m induced system.
Furthermore, our automation of the technique can be leveraged to screen for likely
inhibition candidates that act by preventing the CTI of Pro32. The automated labeling (see
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Appendix) can include the addition of inhibitor molecules. In this way, several inhibitor
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Figure 4.1: HNSB Trp labeling of WT β2m bound to small molecule inhibitors
doxycycline, rifamycin, or EGCG or small molecule binding control suramin. Cu(II) was
used as the amyloid initiator in these cases.
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candidates can be placed in vials within the autosampler. β2m can be mixed with each
candidate at a 0 time point and a time point several hours later. If there is a significant
decrease in HNSB labeling indicating Pro32 CTI after several hours, that compound would
be a good candidate for further testing as to its inhibitory effects.
Several cases have been identified of amyloid forming proteins and peptides crossseeding other amyloid forming systems.21–25 An interesting application of our technique
would be the seeding of WT β2m amyloidosis with another amyloid. Specifically, Aβ and
the prion protein would be good candidates. Aβ is a peptide and would likely be able to
interact with β2m easily. The prion protein is known to be infective and have the ability to
cross-seed other systems and would compare well with ΔN6-β2m.25
Peptide fragments of the β2m sequence have been identified which have shown the
ability to form amyloid-like fibrils on their own as well as induce aggregation in the full
WT protein (Figure 4.2).26 These observations give an opportunity to investigate their
potential to seed WT β2m under both primary and secondary nucleation conditions.
Because each of the peptide fragments are from regions of the full β2m protein, studies of
these peptides could give important insight into which sections of the protein are involved
in primary and secondary nucleation dependent amyloid formation. If the use of one

Figure 4.2: Select peptide fragments of the β2m sequence that are known to aggregate as
well as induce aggregation in the full-length protein
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peptide yields a larger reduction in the activation energy barrier than the others, that would
be an indication of the importance of that stretch of the sequence to the amyloid forming
process under either primary or secondary nucleation conditions.
In addition to the use of mutants R3A, H51F, F30A, and F62A as mentioned in
Chapter 3, other point mutants would be useful in future experiments to reveal regions of
β2m that are most critical to the activation energy of the pre-amyloid structural change
whether induced by Cu(II) or the interaction between WT β2m and ΔN6-β2m. The
amyloidogenesis of several point mutants of β2m have been compared to WT β2m. Most
interestingly D53P27 aggregates to amyloids slower that WT β2m and D59P28 yield
amyloids faster than WT β2m. Our technique would be useful for determining whether
these mutants effect the energy barrier to the Pro32 CTI as induced by Cu(II) or if they are
more critical downstream of the CTI, but before full amyloid formation. D53P is not likely
to greatly affect the CTI as it is far from the region of the protein involved but may slow
aggregation by disrupting oligomerization as it replaces a negatively charged residue with
a neutral residue that introduces a kink into the amino acid chain.
It was demonstrated by Karamanos et al. that the BC, DE, and FG loops (Figure
4.3) are important in the transient head-to-head interactions between WT β2m and ΔN6β2m that lead to amyloidosis.29 However, it is still unclear if any of these three loops are
more critical than the others for this process or the importance of specific residues. The AB
loop has also been shown to be an important driver of monomer association at a range of
pHs.30 Additional point mutants could help shed some light on the importance of these
various loops. H13F and N17D mutants would be valuable for probing the AB loop where
higher mobility of the loop leads to improved adhesion between monomers.30 H13F and
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Figure 4.3: The head of the β2m protein comprised of the N-terminus (green strand), the
BC loop (blue), the DE loop (yellow) including Asp59, and the FG loop (orange) including
His84.
N17D would both likely slow the ΔN6-β2m initiated amyloidosis of WT β2m as they
would promote non-productive interactions between the two proteins. The DE loop (Figure
4.3) can be probed with the D59P mutant which introduces a significant change in size and
charge as well as another proline to a critical region. D59P would likely reduce productive
head-to-head interactions with ΔN6-β2m due to a reduction in the possibility of salt bridge
formation. A dimer-stabilizing intermolecular salt bridge is seen between D59 and K19 of
two WT β2m molecules in the amyloid competent state, of which ΔN6-β2m is a structural
mimic.3,31 The resulting reduction in interaction between ΔN6-β2m and WT β2m would
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then decrease the CTI rate of Pro32. The FG loop (Figure 4.3) can be probed by H84A as
H84 is positively charged and would be replaced by a much smaller, uncharged, and
hydrophobic residue. This mutation would likely result in a decrease in Pro32 CTI rate.
The amyloidogenic mutant D76N-β2m has similar properties to ΔN6-β2m. It is
naturally occurring, self-amyloidogenic, and can also induce amyloidogenicity in the WT
protein.30,32–39 Interestingly, however, D76N-β2m shows only subtle structural differences
from the WT.40 This mutant would be a great candidate for comparing the primary and
secondary nucleation mechanisms in a manner similar to ΔN6-β2m. Such studies would
also contribute to the currently sparse knowledge of the D76N-β2m aggregation
mechanism. Our Trp labeling technique could be applied in almost exactly the same way
as we have investigated ΔN6-β2m. In all, these future works would add to the mechanistic
information of β2m amyloidogenesis we have gained here as well as amyloid systems
generally.
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APPENDIX
AUTOMATION AND USE OF AGILENT 1100 LC SYSTEM FOR COVALENT
LABELING
Set up of 1100 system modules
For all automated covalent labeling (CL) experiments in this dissertation, the
following Agilent 1100 modules were used: G1367A well plate autosampler with
temperature control, G1379A degasser, and G1312A binary pump. Other Agilent 1100
modules can easily be integrated into this setup for a variety of measurements (e.g.,
G1315B diode array detector).
Ensure that each module being used is connected via CAN cable to another module
being used. The chain of CAN cables should end at the module with the networking card.
Good practice dictates that the networking card be in the module that collects data (i.e.,
diode array detector or similar). For our experiments, all data was collected by the mass
spectrometer, therefore any module can have the network card.
Connect the network card to the computer with a crossover shielded LAN patch
cable. When setting up the ethernet adapter on the computer for communication with the
Agilent modules, ensure you match the IP address to that of the Agilent system. This IP
address can be found and/or changed in the settings on the Agilent handheld control
module.
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Vial placement in the well plate autosampler
The vials in the well plate of the autosampler will contain all reagents needed for
the CL reaction. This may include: the protein sample, labeling reagent, quencher, and any
other reagents needed depending on the CL reaction being performed. Vials should be
placed as close to the injection inlet of the autosampler as possible to minimize the injector
needle’s travel time around the compartment. Figure A.1 shows an example well plate set
up for an HNSB labeling reaction on Cu(II) induced β2m. This can be expanded for more
sample vials/more time points, but it is recommended to continue keeping all sample vials
as close to the inlet as possible. This method can be customized to add any and all reagents
needed for a CL procedure.

Figure A.1: Well plate setup for an HNSB labeling reaction on Cu(II) induced β2m.
Included are the HNSB reagent (pink), Cu(II) (green), L-Trp quenching agent (blue), and
β2m protein samples (white) to be incubated with Cu(II) for x minutes.
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Software set up
For all automated CL experiments in this dissertation, Bruker Hystar software was
used to jointly control the LC set up and the mass spectrometers used. However, any
software that supports the integration of Agilent LC systems will work (ChemStation, etc.)
It is critical that the firmware versions on all modules matches. Additionally, the firmware
of all modules may need to be updated or downgraded for compatibility with the software
you choose (see Agilent website for more information).
The gradient and flow rate can be set in the bin pump section of the method. These
will depend on the particular CL reaction and column being used. For our experiments we
used a protein desalting column with a max flow rate of 0.2 mL/min and a short (2 min)

Figure A.2: Example LC gradient for desalting of an HNSB reaction with β2m. It begins
at 3%B until 2 min when it starts to rapidly rise to 70% B. The gradient sits at 70% B until
min 10 to ensure all protein has eluted off the column followed by a slow return to 3% B
at min 15.
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desalting time at 3%B followed by a quick jump to 70% B to release the protein sample
from the column (Figure A.2).
Within the settings for the autosampler part of the method, an ‘injector program’
can be written. This uses command lines such as ‘DRAW’ to pull solution from a vial or
‘EJECT’ to place solution into a different vial. This allows for granular control of the
autosampler allowing it to be used as a pseudo liquid handing robot. In this way, the
autosampler can completely take over all steps of a CL reaction. The following is an
example injector program for an HNSB labeling reaction on Cu(II) induced β2m that goes
with the well plate setup in Figure A.1. In all capital letters are the base commands found
in the programming window and what follows each base command are the variables.
•

VALVE: bypass

•

DRAW: from vial 83, 1 uL, 500 uL/min

•

EJECT: into sample, 500 uL/min

•

NEEDLE: wash in flush port, 1 sec

•

DRAW: from vial 82, 5 uL, 500 uL/min

•

WAIT: x min-22 sec

•

EJECT: into sample, 500 uL/min

•

NEEDLE: wash in flush port, 10 sec

•

DRAW: from vial 81, 4 uL, DEF.

•

WAIT: 14 sec

•

EJECT into sample, DEF.

•

DRAW from sample, 10 uL, DEF.

•

INJECT 10 uL, DEF.

•

VALVE mainpass+start

•

NEEDLE wash in flush port, 10 sec
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Note that the autosampler completes all steps, including initiation with Cu(II),
reaction with HNSB, and quenching with Trp before injecting the sample onto the column.
These commands can be customized for nearly any CL reaction. Note that due to slight
movement differences in each individual autosampler, it is recommended to determine
travel times of the injector needle to various vial locations as this may affect how long the
WAIT steps should be.
Notes
•

Ensure proper cleaning of the system after every experiment. Neglecting this can
lead to clogs in the system.

•

Firmware versions can be update or downgraded using Agilent’s Lab Advisor
software (see Agilent website).
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